WALTHAM, Mass.--(BUSINESS WIRE)--Avedro, Inc. announced today that the Company has entered into an exclusive Option Agreement with the Cleveland Clinic for the right to negotiate a license for 3 specific Intellectual Property (IP) assets to enhance the Company’s existing portfolio of cross-linking therapies and diagnostics. If Avedro licenses this technology it intends to utilize it in the development of the company’s products.
